TransCode Therapeutics appoints RNA expert to advisory board

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of $5.73 million specializing in RNA-targeted cancer treatments, announced today the appointment of Dr. Phillip D. Zamore to its Scientific Advisory Board. According to InvestingPro data, while the company maintains a healthy current ratio of 5.2 and holds more cash than debt, it faces significant financial challenges with rapidly depleting cash reserves. Dr. Zamore brings his expertise as a co-founder of Alnylam Pharmaceuticals and a pioneer in RNA interference (RNAi) technology, which led to the development of the first FDA-approved RNAi drug.

Dr. Zamore, who is the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Chan Medical School, has made significant contributions to the understanding of non-coding RNA. His research has shed light on microRNA processing and its role in gene silencing. His achievements have earned him membership in the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. For investors seeking deeper insights into TransCode’s financial health and growth prospects, InvestingPro offers comprehensive analysis with over 15 additional ProTips and detailed metrics.

"We are honored to welcome Dr. Zamore to our Science Advisory Board," said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. "His deep expertise in RNA biology and his track record of translating scientific discoveries into therapeutic innovations will be invaluable as we advance our pipeline of RNA-targeted cancer therapies."

Dr. Zamore expressed his enthusiasm for TransCode’s innovative approach to treating metastatic cancer through RNA therapeutics. He looks forward to contributing to the company’s development of effective RNA-based treatments for cancer patients.

Trading at $6.87 per share, TransCode is currently focused on advancing its lead therapeutic candidate, TTX-MC138, aimed at treating metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. InvestingPro analysis indicates the company is not expected to be profitable this year, with analysts forecasting an EPS of -$14.87 for 2025. The company also has a portfolio of RNA therapeutic candidates designed to address the challenges of RNA delivery and target a range of genetic factors relevant to various cancers.

The company’s proprietary TTX nanoparticle platform underpins its approach to RNA therapeutics, enabling the design and delivery of treatments intended to combat metastatic disease.

This announcement is based on a press release statement and contains forward-looking statements subject to risks and uncertainties, including the performance of clinical trials and the need for additional funding. The information reflects the company’s expectations as of today.

In other recent news, TransCode Therapeutics has made significant strides in its clinical trial efforts and corporate strategies. The company announced progress in its Phase 1a clinical trial of TTX-MC138, a therapeutic candidate targeting metastatic cancer. Thirteen patients have been treated without significant safety issues, and two participants have maintained stable disease for over seven months. Additionally, TransCode has initiated dosing for the first patient in Cohort 4 of the same trial, marking a further step in assessing the safety and tolerability of escalating doses of TTX-MC138. This dose is approximately fifty percent higher than that of the previous cohort, with no significant safety concerns reported.

In parallel to its clinical advancements, TransCode Therapeutics has approved a reverse stock split at a 1-for-28 ratio to comply with Nasdaq’s listing requirements. This decision will consolidate the company’s shares, reducing the total number from approximately 23.3 million to around 833,620. The reverse stock split is aimed at meeting Nasdaq’s minimum bid price requirement. Vstock Transfer LLC has been appointed as the exchange agent for this process. TransCode’s ongoing developments reflect its focus on advancing RNA therapeutics for metastatic disease treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.